Challenges in managing patients on anticoagulation: Thrombocytopenia,resumption after bleeding and recurrent thrombosis

Abstract

Prescribing of anticoagulation is increasing worldwide. This is partly reflective of an aging population with cardiovascular comorbidities such as arrhythmias and prosthetic heart valves, alongside improvements in cancer treatments and survival. In this review, we discuss three common challenges faced by clinicians. These concern the management of patients with thrombosis and thrombocytopenia, resumption of anticoagulation in patients with a history of gastrointestinal or intracranial haemorrhage, and how to approach and treat a patient with recurrent thrombosis on anticoagulation. We consider the available evidence including relevant published recommendations and propose practical management suggestions to aid clinicians faced with these dilemmas.

Keywords

anticoagulation intracranial haemorrhage gastrointestinal haemorrhage recurrent VTE thrombocytopenia

Get full access to this article

View all access options for this article.

References

van Hove

Leng

Trends in anticoagulant prescribing: a review of local policies in English primary care. BMC Health Serv Res 2020; 20: 279.

Cortelezzi

Moia

Falanga

et al. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study. Br J Haematol 2005; 129: 811–7.

Khorana

Kuderer

Culakova

et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902–7.

Kopolovic

Lee

Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study. Ann Hematol 2015; 94: 329–36.

Samuelson Bannow

Lee

Khorana

et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16: 1246–9.

Kansu

Thrombosis in stem cell transplantation. Hematology 2012; 17: S159–62.

Rodeghiero

Is ITP a thrombophilic disorder?

Am J Hematol 2016; 91: 39–45.

Ruggeri

Tosetto

Palandri

et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost 2014; 12: 1266–73.

Sarpatwari

Bennett

Logie

et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010; 95: 1167–75.

10.

Severinsen

Engebjerg

Farkas

et al. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol 2011; 152: 360–2.

11.

Swan

Newland

Rodegheiro

et al. Thrombosis in immune thrombocytopenia — current status and future perspectives. Br J Haematol 2021; 194: 822–34.

12.

Arepally

Padmanabhan

Heparin-induced thrombocytopenia: a focus on thrombosis. Arterioscler Thromb Vasc Biol 2021; 41: 141–52.

13.

Watson

Davidson

Keeling

Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol 2012; 159: 528–40.

14.

Greinacher

Thiele

Warkentin

et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384: 2092–101.

15.

Mendolicchio

Ruggeri

ZM.

New perspectives on von Willebrand factor functions in hemostasis and thrombosis. Semin Hematol 2005; 42: 5–14.

16.

Scully

Hunt

Benjamin

et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. B J Haematol 2012; 158: 323–35.

17.

Samuelson Bannow

Lee

Khorana

et al. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review. Res Pract Thromb Haemost 2018; 2: 664–9.

18.

Napolitano

Saccullo

Marietta

et al. Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. Blood Transfus 2019; 17: 171–80.

19.

Agnelli

Becattini

Meyer

et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382: 1599–607.

20.

Raskob

van Es

Verhamme

et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2017; 378: 615–24.

21.

Young

Marshall

Thirlwall

et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36: 2017–23.

22.

Rubboli

Becattini

Verheugt

FW.

Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. World J Cardiol 2011; 3: 351–8.

23.

Khanal

Bociek

Chen

et al. Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia. Am J Hematol 2016; 91: E468–72.

24.

Oakland

Chadwick

East

et al. Diagnosis and management of acute lower gastrointestinal bleeding: guidelines from the British Society of Gastroenterology. Gut 2019; 68: 776–89.

25.

Strate

Gralnek

IM.

ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. Am J Gastroenterol 2016; 111: 459–74.

26.

Christensen

Cordonnier

Kõrv

et al. European stroke organisation guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage. Eur Stroke J 2019; 4: 294–306.

27.

Radaelli

Dentali

Repici

et al. Management of anticoagulation in patients with acute gastrointestinal bleeding. Dig Liver Dis 2015; 47: 621–7.

28.

Ruff

Giugliano

Braunwald

et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–62.

29.

Granger

Alexander

McMurray

et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–92.

30.

Giugliano

Ruff

Braunwald

et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–104.

31.

Ageno

Vedovati

Cohen

et al. Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the caravaggio study. Thromb Haemost 2021; 121: 616–24.

32.

Lane

Lip

GY.

Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation 2012; 126: 860–5.

33.

Witt

Delate

Garcia

et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012; 172: 1484–91.

34.

Qureshi

Mittal

Patsias

et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol 2014; 113: 662–8.

35.

Patsias

Mittal

Elbatta

et al. Optimal duration to restart warfarin after discontinuation of therapy in atrial fibrillation patients that developed gastrointestinal bleeding. J Am Coll Cardiol 2013; 61: E342.

36.

Sengupta

Feuerstein

Patwardhan

et al. The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. Am J Gastroenterol 2015; 110: 328–35.

37.

Laine

Barkun

Saltzman

et al. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. J Am Gastroenterol 2021; 116: 899–917.

38.

Schulman

Beyth

Kearon

et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: american college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 257S–98S.

39.

Wilson

Seiffge

Traenka

et al. Outcome of intracerebral hemorrhage associated with different oral anticoagulants. Neurology 2017; 88: 1693–700.

40.

Seiffge

Goeldlin

Tatlisumak

et al. Meta-analysis of haematoma volume, haematoma expansion and mortality in intracerebral haemorrhage associated with oral anticoagulant use. J Neurol 2019; 266: 3126–35.

41.

Nielsen

Larsen

Skjøth

et al. Outcomes associated with resuming warfarin treatment after hemorrhagic stroke or traumatic intracranial hemorrhage in patients with atrial fibrillation. JAMA Intern Med 2017; 177: 563–70.

42.

Al-Shahi Salman

Keerie

Stephen

et al. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurol 2021; 20: 842–53.

43.

Hawryluk

Austin

Furlan

et al. Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk. J Thromb Haemost 2010; 8: 1500–8.

44.

Majeed

Kim

Roberts

et al. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 2010; 41: 2860–6.

45.

Steiner

Al-Shahi Salman

Beer

et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke 2014; 9: 840–55.

46.

Kirchhof

Benussi

Kotecha

et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893–962.

47.

Hemphill

Greenberg

Anderson

et al. Guidelines for the management of spontaneous intracerebral hemorrhage. Stroke 2015; 46: 2032–60.

48.

Lobo

Jiménez

Teresa Orue

et al. Recurrent venous thromboembolism during coumarin therapy. Data from the computerised registry of patients with venous thromboembolism. Br J Haematol 2007; 138: 400–3.

49.

Kiladjian

Cervantes

Leebeek

et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008; 111: 4922–9.

50.

Hill

Kelly

Hillmen

Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood 2013; 121: 4985–96.

51.

Thachil

Recurrent venous thromboembolism while on anticoagulant therapy. Blood Rev 2012; 26: 175–81.

52.

Lee

Levine

Baker

et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–53.

53.

Agnelli

Becattini

Bauersachs

et al. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the caravaggio study. Thromb Haemost 2018; 118: 1668–78.

54.

Key

Khorana

Kuderer

et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020; 38: 496–520.

55.

Wang

Zwicker

et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH. J Thromb Haemost 2019; 17: 1772–8.

56.

Pengo

Hoxha

Andreoli

et al. Trial of rivaroxaban in antiPhospholipid syndrome (TRAPS): two-year outcomes after the study closure. J Thromb Haemost 2021; 19: 531–5.

57.

Kubitza

Becka

Zuehlsdorf

et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006; 46: 549–58.

58.

Martin

Lee

Farrell

et al. Oral anticoagulant use after bariatric surgery: a literature review and clinical guidance. Am J Med 2017; 130: 517–24.

59.

Keeling

Baglin

Tait

et al. Guidelines on oral anticoagulation with warfarin – fourth edition. Br J Haematol 2011; 154: 311–24.

60.

Carrier

Le Gal

Cho

et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 2009; 7: 760–5.